Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Auxilium Pharmaceuticals Inc. Stories

2014-02-05 08:28:25

CHESTERBROOK, Pa., Feb. 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Leerink Swann Global Healthcare Conference to be held February 11-13, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to participate in a discussion about the Company at 10:40...

2014-02-03 08:26:54

CHESTERBROOK, Pa., Feb. 3, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the BIO CEO & Investor Conference to be held February 10-11, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9...

2014-01-08 08:27:31

CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the executive management team will participate in the J.P. Morgan 32(nd) Annual Healthcare Conference to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 4...

2014-01-08 08:27:28

Data Show Recurrent Hand Contractures Treated Successfully in Nearly 90 Percent of Patients; Retreatment Shown to be Well-Tolerated CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX® (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture (DC) and a...

2013-12-20 08:25:18

sBLA Submitted for Dupuytren's Contracture, a Progressive Hand Disease that Can Present with Multiple Collagen "Cords" That Limit Movement and Function CHESTERBROOK, Pa., Dec. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) requesting approval of XIAFLEX (collagenase...

2013-12-13 08:25:24

LYNBROOK, N.Y., Dec. 13, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of frozen shoulder syndrome (adhesive capsulitis)....

2013-12-13 08:24:40

CHESTERBROOK, Pa., Dec. 13, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the first patient was dosed in its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome (FSS). FSS can be a prolonged, painful condition of the shoulder in which increased capsular collagen thickening...

2013-12-06 16:23:39

LYNBROOK, N.Y., Dec. 6, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S and XIAPEX(®) in the EU, today announced that the U.S. Food & Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium)...

2013-12-06 16:23:15

XIAFLEX is First and Only FDA-Approved Treatment Proven Effective for Peyronie's Disease CHESTERBROOK, Pa., Dec. 6, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved XIAFLEX(®) (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease (PD). XIAFLEX is the first and only FDA-approved...

2013-12-05 16:25:29

CHESTERBROOK, Pa., Dec. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the Oppenheimer 24(th) Annual Conference to be held December 10-11, 2013 at the Crown Plaza in New York. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30 a.m. ET on Wednesday, December 11, 2013. (Logo:...